Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)
N/A
N/A
N/A
N/A
N/A
Not Enrolling
Both
Non-Small Cell Lung Cancer
Both
Non-Small Cell Lung Cancer
Trial Information
Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)
Inclusion Criteria:
- Participation in the gefitinib Expanded Access Program
- Patient still uses gefitinib in September 2009
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Retrospective
Outcome Measure:
The following characteristics of the 'long-term responders' from the EAP; gender, ethnicity, smoking history (pack years), EGFR-TK mutation and histology of NSCLC.
Outcome Time Frame:
Characteristics will be recorded once, retrospectively
Safety Issue:
No
Authority:
Netherlands: Medical Ethics Review Committee (METC)
Study ID:
NIS-ONL-IRE-2009/1
NCT ID:
NCT01103089
Start Date:
March 2010
Completion Date:
December 2010
Related Keywords:
- Non-Small Cell Lung Cancer
- NSCLC
- EGFR
- gefitinib
- observational
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
